Three Semaglutides: How One Molecule Split Into Three Legal Categories

One molecule, three identities. The peptide that newspapers call semaglutide can sit in a pharmacy as an approved injectable, in a compounding lab as a shortage-era substitute, or on a laboratory bench as a characterised reference standard — and the law treats these as three different things, even when the chemistry overlaps. The distinction is not pedantry. It is the whole story.

How did one drug end up with three legal personalities?

The split was an accident of supply. During the 2022–2024 GLP-1 shortage, US compounding pharmacies operating under section 503A, and outsourcing facilities under 503B, were temporarily permitted to compound semaglutide and tirzepatide.¹ That permission existed only because the approved products could not meet demand. It was a regulatory pressure valve, not a new category of medicine.¹

The mechanics matter here, because they explain why the permission was always temporary. The carve-out that lets a compounder prepare a copy of an approved drug exists only while that drug sits on the FDA’s official shortage list. Compounding a near-copy of a commercially available, approved product is otherwise tightly restricted; the shortage listing is the specific condition that suspends that restriction.¹ Remove the drug from the list, and the legal foundation for compounding it disappears with it.

The valve has since closed. The FDA declared the tirzepatide shortage resolved in December 2024, and the semaglutide shortage resolved on 21 February 2025.² What followed were dated enforcement wind-downs — explicit deadlines to stop compounding rather than an abrupt cut-off.¹

The three categories that now attach to semaglutide, built strictly from the verified regulatory record. They differ in legal status, oversight, and intended use.

What exactly are the wind-down deadlines?

To read the four dates, it helps to know that 503A and 503B are not the same kind of business. A 503A is a traditional compounding pharmacy preparing patient-specific medicines, typically against an individual prescription. A 503B is a registered outsourcing facility that compounds in larger batches and operates under tighter manufacturing oversight.¹ The FDA wound the two down on separate clocks, and treated each compound separately, which is why there are four staggered deadlines rather than one.

For tirzepatide, 503A pharmacies were told to stop compounding by 19 February 2025 and 503B facilities by 19 March 2025.²³ For semaglutide, the 503A deadline fell on 22 April 2025 and the 503B deadline on 22 May 2025.²⁴ After those dates, the shortage-era permission no longer applied to that category of facility.

21 Feb 2025 the date the FDA declared the semaglutide shortage resolved — the trigger that started the compounding wind-down clock.²

The agency then went further. It has proposed to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B bulk-drug-substances list.¹ If finalised, that exclusion would bar 503B outsourcing facilities from compounding these molecules regardless of any future shortage — a structural change, not a temporary one.¹ The usual escape hatch, a fresh shortage declaration, would simply not reopen the door for those facilities.

A shared molecular formula is not a shared legal status. The chemistry is the least interesting thing these three categories have in common.

Why isn’t research-grade material just a cheaper version of the medicine?

This is the costly misconception, and it is worth stating plainly. Research-grade or research-use-only (RUO) material is not a cheaper version of the approved medicine, and it is not interchangeable with it. The three categories differ across every axis that matters: legal status, regulatory oversight, and intended use.

It is worth being concrete about what “characterised analytical standard” actually means, because the phrase does a lot of work. A reference material is a substance whose identity and purity have been established by analytical methods, so that it can serve as a known point of comparison on the bench — the yardstick against which an assay, a chromatogram or an instrument reading is calibrated. Its value lies entirely in being a documented, consistent comparator for laboratory work. That is a different proposition from a medicine, which is defined by its authorised use in people, not by its role as a measurement reference.

An approved medicine carries a marketing authorisation, a regulated supply chain, and a labelled indication for patients under prescription. A compounded preparation was a pharmacist’s response to a supply gap, governed by 503A or 503B rules and now wound down.¹ A research-grade reference material is something else entirely: a characterised analytical standard, intended for the bench and never for human use. Confusing the third with the first is not a bargain — it is a category error.

• Legal status: approved licensed medicine versus shortage-era stopgap versus non-medicinal reference material.
• Oversight: marketing authorisation, compounding-facility rules, and analytical-standard handling are three separate regimes.
• Intended use: the patient, the now-closed substitute, and the laboratory respectively.

What remains genuinely uncertain?

Two honest caveats. First, the permanent 503B exclusion is a proposal. It signals clear regulatory intent, but until it is finalised it is not settled law, and the precise scope could shift. Second, the resolved-shortage status and the dated wind-downs describe the position as recorded — they do not predict future supply, future shortage declarations, or how enforcement will play out in practice. We flag these gaps rather than paper over them; overstating a regulatory claim would be the worse error.

For the bench, the practical takeaway is simpler than the legal map. Condor Research supplies research-grade reference materials strictly for research use only — characterised analytical standards for laboratory work, not the approved, regulated medicine and not the compounded preparation that shortage rules once permitted. These items are for the bench, not the body, and are not intended for human use. That distinction is the brand.